Condition 1: Trichomonas vaginitis. Condition 2: Trichomonas vaginitis. Urogenital trichomoniasis Urogenital trichomoniasis
Conditions
Interventions
Intervention 1: vaginal probiotic capsule,once daily until 10 day. Intervention 2: Control group: standard treatment with oral metronidazole 250 mg tablet every 12 hours, 2 to 7 days.
Treatment - Drugs
vaginal probiotic capsule,once daily until 10 day
Control group: standard treatment with oral metronidazole 250 mg tablet every 12 hours, 2 to 7 days.
Sponsors
Deputy for Research of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria of the study: Non-pregnant, non-lactating, and non-smoker women who aged between 18 and 55, being married, being willing to participate in the research, being in the follicular phase of the menstrual cycle, having signs of trichomoniasis on physical examination, having signs of bacterial vaginosis on physical examination, not having abnormal vaginal bleeding at the time of sampling, not having vaginal intercourse and douching during 48 hours prior to the study, not taking vaginal medication, such as creams, suppositories, and vaginal disinfectants in 48 hours before the study, not taking medication for treatment during the last 3 months, not suffering from specific diseases, such as liver, heart, and kidney diseases, diabetes, central nervous system diseases, blood discrasia, immune system defects, and known sexually transmitted diseases, not having used broad-spectrum antibiotics, anti-prostaglandins, hormone and immunosuppressive drugs, alcohol, and anticoagulation in recent months, no history of sensitivity to metronidazole tablets, not having vulvovaginitis four or more times during the year, and not having multiple sexual partners. Exclusion criteria of the study: Having allergy to the elements of the probiotic products which were used in the study, being considered unhealthy based on the clinical diagnosis, while having negative test results, and having allergy to the medication compounds used in the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gram stain,wet smear and clinical signs. Timepoint: Before intervention,1week and 10 days after intervention. Method of measurement: questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: 7-10 days after intervention. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKhadijeh Abdali
Fatemeh (PBUH) College of Nursing and Midwifery, Shiraz
Outcome results
None listed